Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03214380 · ClinicalTrials.gov registry record · Phase 3
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 933
- Enrollment target
NCT03214380: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT03214380 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 933 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03214380, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 933 participants
- Enrollment target
Study Summary
The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
Primary Outcome
Change from baseline in HbA1c was performed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.
Interventions
- DRUG Metformin
- DRUG Insulin Glargine
- DRUG Insulin Degludec
- DRUG Insulin Lispro
- DRUG LY900014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 933 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2019-03-13 |
| Phase | Phase 3 |
What the finished NCT03214380 record still lists
NCT03214380 is an interventional study that assigns participants to a tested intervention. The registered 933 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% higher).
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT03214380 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03214380 about?
NCT03214380 is a clinical study titled "A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes". The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
What is the current status of trial NCT03214380?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 933 participants. The study started on 2017-07-14. Estimated completion is 2019-03-13.
What interventions are being tested in trial NCT03214380?
The interventions under investigation include: Metformin (DRUG), Insulin Glargine (DRUG), Insulin Degludec (DRUG), Insulin Lispro (DRUG), LY900014 (DRUG).
Who is sponsoring clinical trial NCT03214380?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03214380's enrollment target sits among peer trials
933 338th of 2000 higher than 1,663 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- NCT05519007 · 936 participants · NA
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI